SCHEMBL1701829

SCHEMBL1701829

COc1ccc(Nc2cnc3ccccc3c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 6/20 0.73
ALPL P05186 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 2/20 0.55
KDM4E B2RXH2 4/20 0.54
GAA P10253 2/20 0.54
ALDH1A1 P00352 1/20 0.54
KMT2A Q03164 4/20 0.54
POLB P06746 2/20 0.54
KDM1A O60341 1/20 0.54
RAD52 P43351 1/20 0.54
GFER P55789 1/20 0.54
MAPT P10636 3/20 0.52
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
THRB P10828 1/20 0.52
MAPK1 P28482 1/20 0.52
RECQL P46063 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21282169 0.84 PIK3CA (0.55) IGF1RALPLSMN1; SMN2LMNAKDM4E
SCHEMBL28857363 0.82 ALDH1A1 (0.58) IGF1RSMN1; SMN2LMNAKDM4EGAA
SCHEMBL2111139 0.82 KDM4E (0.58) IGF1RSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL28243562 0.82 NPC1 (0.66) IGF1RKDM4EGAAALDH1A1KMT2A
SCHEMBL1701968 0.81 IGF1R (0.60) IGF1RALPLSMN1; SMN2KMT2AMAPT
SCHEMBL28048000 0.80 PDGFRB (0.61) IGF1RALPLSMN1; SMN2LMNAKDM4E
SCHEMBL4817314 0.80 NPSR1 (0.54) IGF1RSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL16388916 0.79 IGF1R (0.50) IGF1RSMN1; SMN2LMNAKDM4EGAA
SCHEMBL14300546 0.79 ALDH1A1 (0.68) KDM4EGAAALDH1A1KMT2APOLB
SCHEMBL30273062 0.79 ALDH1A1 (0.68) KDM4EGAAALDH1A1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440546-B1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA ABIVAX (FR) 2022-12-28 EP claimed
US-9827237-B2 Compounds useful for treating diseases caused by retroviruses ABIVAX (FR) 2017-11-28 US claimed
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-06-02 US claimed
EP-3016656-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-05-11 EP claimed
CN-105530938-A Compounds for the treatment of diseases caused by retroviruses ABIVAX 2016-04-27 CN claimed
US-9108919-B2 Compounds useful for treating cancer ABIVAX (FR) 2015-08-18 US claimed
WO-2015001518-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES SPLICOS (FR) 2015-01-08 WO claimed
US-20140080831-A1 COMPOUNDS USEFUL FOR TREATING CANCER CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2014-03-20 US claimed
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIETE SPLICOS (FR) 2012-12-27 US claimed
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS SOCIETE SPLICOS (FR) 2012-11-08 US claimed
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER SOCIETE SPLICOS (FR) 2012-11-01 US claimed
EP-2440546-A2 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA Société Splicos (FR) 2012-04-18 EP claimed
WO-2010143169-A2 COMPOUNDS USEFUL FOR TREATING AIDS SOCIÉTÉ SPLICOS (FR) 2010-12-16 WO claimed
WO-2010143170-A2 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIÉTÉ SPLICOS (FR) 2010-12-16 WO claimed
US-20240343716-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING ABIVAX (FR) 2024-10-17 US disclosed
EP-3521283-B1 COMPOUNDS USEFUL FOR TREATING CANCER ABIVAX (FR) 2024-02-28 EP disclosed
EP-3517534-B1 COMPOUNDS USEFUL FOR TREATING CANCER ABIVAX (FR) 2024-02-28 EP disclosed
WO-2010143169-A2 COMPOUNDS USEFUL FOR TREATING AIDS SOCIÉTÉ SPLICOS (FR) 2010-12-16 WO disclosed
WO-2010143169-A2 COMPOUNDS USEFUL FOR TREATING AIDS SOCIÉTÉ SPLICOS (FR) 2010-12-16 WO disclosed
WO-2010143170-A2 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIÉTÉ SPLICOS (FR) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS CBR1, CNR1, CBR3 IGF1R 4276/4885ALPL 4857/4885SMN1; SMN2 4559/4885
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER CBR1, CBR3, NCOR1 IGF1R 2609/4885ALPL 4878/4885SMN1; SMN2 4495/4885
US-20240343716-A1 COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING RCOR1, NR3C1, NR5A1 IGF1R 700/4885ALPL 4874/4885SMN1; SMN2 3125/4885
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA NR2C2, NCOR2, NR4A2 IGF1R 1219/4885ALPL 4770/4885SMN1; SMN2 1391/4885
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES RCOR1, CBR1, RCOR3 IGF1R 3471/4885ALPL 4870/4885SMN1; SMN2 2094/4885
US-20140080831-A1 COMPOUNDS USEFUL FOR TREATING CANCER NR1H4, NR1H3, NCOR1 IGF1R 609/4885ALPL 4857/4885SMN1; SMN2 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.